in the section entitled “Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2011 as filed with the SEC on August 26, 2011, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
CONTACTS:
James Winschel, Senior Vice President and Chief Financial OfficerJill Baker, Corporate Vice President, Investor Relations+1-781-434-4118PAREXEL International Corporation Consolidated Condensed Statement of OperationsUnauditedThree Months EndedThree Months Ended(in thousands, except per share data)September 30, 2011September 30, 2010As ReportedAdjustmentsNon-GAAPAs ReportedAdjustmentsNon-GAAPService revenue$
314,735$
-$ 314,735$
295,820$
-$ 295,820Reimbursement revenue45,91445,91446,43746,437 Total revenue360,649-360,649342,257-342,257Costs and expenses:Direct costs222,174222,174189,644
(a)189,644Reimbursable out-of-pocket expenses45,91445,91446,43746,437Selling, general and administrative 60,98960,98960,858
(a)60,858Depreciation14,28114,28113,25113,251Amortization2,1412,1412,4572,457Restructuring charge (benefit)2,700(2,700)
(b)
-(390)390
(c)
- Total costs and expenses348,199(2,700)345,499312,257390312,647Income from operations12,4502,70015,15030,000(390)29,610Other (expense) income1,624-1,624(7,315)-(7,315)Income before income taxes14,0742,70016,77422,685(390)22,295Provision for income tax expense4,513533
(d)
5,0464,894(110)
(d)
4,784Effective tax rate32.1%30.1%21.6%21.5%Net income$
9,561$
2,167$
,728$
7,791$
(280)$
7,511Earnings
'/>"/>
SOURCE PAREXEL International Corporation Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related medicine technology :1.
PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value2.
New PAREXEL Podcast Series to Deliver Clinical Development and Commercialization Thought Leadership3.
PAREXEL and National University of Singapore Establish Program in Singapore to Meet Increasing Demand in Asia for Clinical Research Talent4.
PAREXEL Announces Date of First Quarter Fiscal Year 2012 Earnings Release and Conference Call5.
Experts to Provide Successful Strategies for Global Biopharmaceutical Development and Commercialization at PAREXEL Tokyo Seminar6.
PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results7.
PAREXEL Achieves 100th Asian Ethnobridging Study Milestone8.
PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2011 Earnings Release and Conference Call9.
PAREXEL International to Present at Goldman Sachs Healthcare Conference and Jefferies Global Healthcare Conference10.
PAREXEL Invites Public to Listen to Live Webcast of Its Investor Day June 2, 201111.
PAREXEL Reports Third Quarter Fiscal Year 2011 Financial Results